The Current State of Stem Cell Therapeutics: Canadian Approaches in the International Context

Abstract After ischemic injury, the endogenous repair mechanisms of the human heart are insufficient for meaningful tissue regeneration, so muscle lost is replaced by noncontractile scar tissue. Current treatments for ischemic cardiomyopathy improve quality of life and increase life expectancy, but...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of cardiology 2014-11, Vol.30 (11), p.1361-1369
Main Authors: Noiseux, Nicolas, MD, MSc, Marquis-Gravel, Guillaume, MD, MSc, Mansour, Samer, MD, Shahzad, Uswa, MSc, Stewart, Duncan J., MD, Yau, Terrence M., MD, MSc
Format: Article
Language:English
Subjects:
Animals
Canada
Cardiovascular
Cell Differentiation
Cell- and Tissue-Based Therapy - methods
Heart Diseases - therapy
Humans
Myocytes, Cardiac - cytology
Stem Cell Transplantation - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract After ischemic injury, the endogenous repair mechanisms of the human heart are insufficient for meaningful tissue regeneration, so muscle lost is replaced by noncontractile scar tissue. Current treatments for ischemic cardiomyopathy improve quality of life and increase life expectancy, but cannot cure the underlying disease of cardiomyocyte loss. Cellular transplantation is emerging as a valuable therapeutic approach to heal the ischemic heart. Adult bone marrow stem cells are capable of differentiation, regeneration of infarcted myocardium, and induction of myogenesis and angiogenesis, ultimately leading to improved contractility. Positive results from animal studies have prompted several clinical trials to ascertain the safety and feasibility of cell therapy. However, despite all the excitement in stem cell research resulting from initial experimental data and preliminary clinical trials, the mixed results observed have raised many unanswered questions. A major obstacle to the identification of the optimal cell therapy is that the fate of the implanted cells and the nature of their beneficial effects are ill-defined. A better understanding is fundamental for the development of new therapeutic agents, and to optimize stem cell applications. Well-designed and powered double-blinded randomized studies are clearly needed to confirm promising findings from early studies. With several ongoing randomized trials directed toward evaluation of stem cell therapies in patients with acute or chronic ischemic cardiomyopathy, the Canadian initiative represents a milestone.
ISSN:0828-282X
1916-7075
DOI:10.1016/j.cjca.2014.04.031